Cytokinetics director sells 5,000 shares at $71.48

Rhea-AI Filing Summary

CYTOKINETICS INC (CYTK) director Lynne B. Parshall reported selling 5,000 shares of common stock on 2026-09-01 in an open market or private transaction at $71.48 per share. After this sale, Parshall holds 10,784 shares of CYTK common stock directly. The filing affirms the transaction was made under a Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares

Net Sell 1 txn

Insider PARSHALL B LYNNE

Role Director

Sold 5,000 shs ($357K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,000	$71.48	$357K

Holdings After Transaction: Common Stock — 10,784 shares (Direct)

Key Figures

Shares sold: 5,000 shares Sale price per share: $71.48 per share Shares owned after transaction: 10,784 shares +1 more

4 metrics

Shares sold 5,000 shares Common Stock sale reported on 2026-09-01

Sale price per share $71.48 per share Price for the 5,000-share sale on 2026-09-01

Shares owned after transaction 10,784 shares Direct holdings of Lynne B. Parshall following the sale

Net buy/sell shares 5,000 shares sold Net insider activity in this Form 4

Key Terms

Rule 10b5-1 trading plan, Form 4, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"the filing affirms the transaction was made under a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Form 4 regulatory

"as disclosed in a Form 4 filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open market or private transaction market

"Sale in open market or private transaction"

FAQ

What insider transaction did CYTK director Lynne B. Parshall report?

Lynne B. Parshall reported a sale of 5,000 CYTK shares of common stock on 2026-09-01 in an open market or private transaction at $71.48 per share, as disclosed in a Form 4 filing.

How many CYTK shares did Lynne B. Parshall sell and at what price?

Lynne B. Parshall sold 5,000 shares of CYTOKINETICS INC (CYTK) common stock at $71.48 per share, according to the reported Form 4 transaction.

What are Lynne B. Parshall’s CYTK holdings after the reported sale?

After the reported sale, Lynne B. Parshall directly holds 10,784 shares of CYTOKINETICS INC (CYTK) common stock, as shown in the Form 4 filing.

Was the CYTK insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 for CYTOKINETICS INC (CYTK) indicates that the reported transaction was conducted under a Rule 10b5-1 trading plan, as evidenced by the affirmative 10b5-1 checkbox.

What is the overall direction of insider activity in this CYTK Form 4?

The Form 4 for CYTOKINETICS INC (CYTK) shows one sale transaction totaling 5,000 shares sold and no purchases, resulting in a net-sell position for this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:52 PM Accepted by SEC EDGAR 09/01/2026 - 04:51 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PARSHALL B LYNNE

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		S		5,000	D	$71.48	10,784	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Ms. Parshall	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)